Please try another search
For the three months ended 31 March 2022, HK Inno.N Corp revenues decreased 4% to W180.21B. Net income decreased 11% to W7.4B. Revenues reflect specific medicines segment decrease of 6% to W161.71B, South Korea (Country) segment decrease of 4% to W173.77B, Japan (Country) segment decrease of 50% to W1.32B. Net income also reflects specific medicines segment income decrease of 68% to W4.73B.
Period Ending: | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
---|---|---|---|---|
Total Revenue | 198166.15 | 251865.94 | 180212.68 | |
Gross Profit | 93432.12 | 98426.84 | 72669.08 | 83650.62 |
Operating Income | 22257.62 | 17657.87 | 4230.24 | |
Net Income | 14961.2 | 13484.12 | 7396.83 | 9039.4 |
Period Ending: | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
---|---|---|---|---|
Total Assets | 1777926.05 | 1802531.74 | 1791745.61 | 1837502.91 |
Total Liabilities | 620521.15 | 660208.61 | 662917.2 | 686548.66 |
Total Equity | 1157404.89 | 1142323.13 | 1128828.41 | 1150954.25 |
Period Ending: | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 23723.92 | 15184.41 | -11173.23 | |
Cash From Investing Activities | -29063.55 | 10.93 | 106888.93 | |
Cash From Financing Activities | -5576.62 | -61013.56 | -29667.75 | |
Net Change in Cash | -10571.3 | -45797.49 | 66055.34 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review